NCT06966622

Brief Summary

Implantable collamer lens (ICL) implantation is considered one of the most effective surgical treatments for high myopia. The procedure primarily involves adjusting the position of the ICL within the eye. However, precise calculation of the ICL optical power may cause the surgical light source to remain focused on the macular area during this process, potentially leading to iatrogenic light-induced damage. Theoretically, the combination of a 3D visualization surgical system and coaxial illumination technology can reduce the illumination intensity and decrease iatrogenic light damage. This study aims to compare the retinal physiological changes in patients undergoing ICL surgery through 3D visualization surgical system with coaxial illumination versus a traditional microscope with standard illumination.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
0mo left

Started Aug 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Aug 2025May 2026

First Submitted

Initial submission to the registry

May 4, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 13, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

August 25, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Expected
Last Updated

August 8, 2025

Status Verified

May 1, 2025

Enrollment Period

3 months

First QC Date

May 4, 2025

Last Update Submit

August 7, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • b-wave amplitude

    1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op

Secondary Outcomes (4)

  • a-wave amplitude

    1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op

  • macular vessel density

    1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op

  • Uncorrected visual acuity

    1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op

  • Best-corrected visual acuity

    1 day pre-op; 1 day post-op; 7 days post-op; 30 days post-op

Other Outcomes (2)

  • Intraoperative illumination intensity

    surgery beginning

  • Surgical time

    Starting with the making of the surgical incision and ending with incision closure

Study Arms (2)

3D visualization system

EXPERIMENTAL
Procedure: 3D visualization system with coaxial illumination

Microscope

ACTIVE COMPARATOR
Procedure: microscope with standard illumination

Interventions

operation through 3D visualization system with coaxial illumination

3D visualization system

operation through microscope with standard illumination

Microscope

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Clinical diagnosis of high myopic
  • Aged 18-40 years
  • Desire to improve their refractive status via ICL surgery
  • Relatively stable refractive error (change ≤ 0.50 D per year for two consecutive years)
  • Central anterior chamber depth ≥ 2.8 mm
  • Open angles
  • Corneal endothelial cell density ≥ 2000 cells/mm2.

You may not qualify if:

  • Cataracts
  • Corneal diseases,
  • Glaucoma,
  • Nystagmus,
  • Strabismus,
  • Lens subluxation,
  • Severe vitreoretinal diseases,
  • Other ocular diseases
  • A history of ocular trauma
  • A history of ocular surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 4, 2025

First Posted

May 13, 2025

Study Start

August 25, 2025

Primary Completion

November 30, 2025

Study Completion (Estimated)

May 31, 2026

Last Updated

August 8, 2025

Record last verified: 2025-05